T. Maemoto

Species differences in brain adenosine A1 receptor pharmacology revealed by use of xanthine and pyrazolopyridine based antagonists

S. Butcher, H. J. Olverman, R. Horton, 1997, British journal of pharmacology.

A Novel Potent Radical Scavenger, 8-(4-Fluorophenyl)-2-((2E)-3-phenyl-2-propenoyl)-1,2,3,4-tetrahydropyrazolo[5,1-c] [1,2,4]triazine (FR210575), Prevents Neuronal Cell Death in Cultured Primary Neurons and Attenuates Brain Injury after Focal Ischemia in Rats

A. Iwashita, N. Matsuoka, I. Shima, 2003, Journal of Pharmacology and Experimental Therapeutics.

Neuroprotective efficacy of FR901459, a novel derivative of cyclosporin A, in in vitro mitochondrial damage and in vivo transient cerebral ischemia models

Y. Furuichi, M. Hino, N. Matsuoka, 2007, Brain Research.

Pyrazolopyridine derivatives act as competitive antagonists of brain adenosine A1 receptors: [35S]GTPgammaS binding studies.

S. Butcher, H. J. Olverman, K. Finlayson, 1999, European journal of pharmacology.

Novel neuroprotective compound SCH-20148 rescues thymocytes and SH-SY5Y cells from thapsigargin-induced mitochondrial membrane potential reduction and cell death.

A. Iwashita, N. Matsuoka, Y. Muramatsu, 2007, European journal of pharmacology.

Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors.

A. Iwashita, T. Yamaji, T. Mihara, 2004, Journal of pharmacological sciences.

Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques.

S. Butcher, H. J. Olverman, H. Marston, 1998, The Journal of pharmacology and experimental therapeutics.

Comparison of effects of MgCl2 and Gpp(NH)p on antagonist and agonist radioligand binding to adenosine A1 receptors.

S. Butcher, H. J. Olverman, K. Finlayson, 2003, Acta Pharmacologica Sinica.